Azitra (AZTR) Net Cash Flow (2022 - 2026)
Azitra's (AZTR) quarterly Net Cash Flow came in at $8.0 million in Q1 2026, up 692.2% YoY from $1.0 million in Q1 2025, and up 1056.39% on a QoQ basis from $690330.0 in Q4 2025.
Azitra (AZTR) Net Cash Flow (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Net Cash Flow data on file, last reported at $8.0 million in Q1 2026.
- Quarterly Net Cash Flow rose 692.2% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (up 3241.45% YoY) and the FY2025 annual result came in at -$2.5 million, down 189.26% from the prior year.
- Net Cash Flow grew to $8.0 million in Q1 2026, from $690330.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $8.0 million in Q1 2026 to a low of -$2.7 million in Q4 2024.
- A 5-year average of $421586.3 and a median of -$1.3 million in 2025 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2025 — Net Cash Flow plunged 211.85% — and 2026, when it soared 692.2%.
- Tracing AZTR's Net Cash Flow over 5 years: stood at -$2.4 million in 2022, then declined by 6.49% to -$2.6 million in 2023, then slipped by 3.88% to -$2.7 million in 2024, then jumped by 125.52% to $690330.0 in 2025, then surged by 1056.39% to $8.0 million in 2026.
- The last three Net Cash Flow figures came in at $8.0 million (Q1 2026), $690330.0 (Q4 2025), and $356148.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | -3.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.33 Mn |
| Jun 30, 2026 | -3.33 Mn |
| Mar 31, 2026 | 7.98 Mn |
| Mar 31, 2026 | 7.98 Mn |
| Dec 31, 2025 | 690,330.00 |
| Dec 31, 2025 | 690,330.00 |
| Sep 30, 2025 | 356,148.00 |
| Sep 30, 2025 | 356,148.00 |
| Jun 30, 2025 | -2.16 Mn |
| Jun 30, 2025 | -2.16 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Mar 31, 2025 | -1.35 Mn |
| Dec 31, 2024 | -2.71 Mn |
| Dec 31, 2024 | -2.71 Mn |
| Sep 30, 2024 | 6.46 Mn |
| Sep 30, 2024 | 6.46 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Jun 30, 2024 | -2.20 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.21 Mn |